Xencor Inc. is a Xencor Inc is a clinical-stage biopharmaceutical company based in the United States.
Xencor Inc. (XNCR) had a good day on the market for Tuesday December 08 as shares jumped 6.31% to close at $41.30. About 408,818 shares traded hands on 5,828 trades for the day, compared with an average daily volume of n/a shares out of a total float of 57.46 million. After opening the trading day at $38.89, shares of Xencor Inc. stayed within a range of $42.51 to $38.70.
With today’s gains, Xencor Inc. now has a market cap of $2.37 billion. Shares of Xencor Inc. have been trading within a range of $43.91 and $19.36 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. Xencor earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Xencor Inc. is based out of Monrovia, CA and has some 166 employees. Its CEO is Bassil I. Dahiyat.